Aβ injection model of AD
Background information: Intracerebral injection of amyloid beta peptide (Aβ) leads to cognitive deficits and reproduces most aspects of the molecular, cellular, and vascular changes occurring in the AD human brain.
Animals: Male Wistar rats.
Aβ injection: Bilateral intrahippocampal injection of Aβ1–42 (5 µg x 2) on Day 0.
Efficacy test: Test articles are administered from Day 1 to Day 24 and efficacy is assessed at specified time points.
Behavioral readouts: Short term memory (T-maze; Day 10), Spatial learning, Retention memory and Flexibility learning (Morris Water Maze; Day 14-18), and Recognition memory (Novel Object Recognition test; Day 21-23).
Positive control: Sigma-2 receptor antagonist.
Criteria for significance: ANOVA followed by Dunnett’s test is applied for comparison between the vehicle and treatment groups. Significant activity is considered at the P<0.05 level. # vs Control, * vs AD.
Turnaround time: 120 Days.